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mise surveillance. We evaluated the contribution of phar-
macy data in three different managed-care settings and
geographic areas. Persons with more than two anti-TB
medications were identified by using pharmacy databases.
Active TB was confirmed by using state TB registries, med-
ical record review, or questionnaires from prescribing
physicians. We identified 207 active TB cases, including 13
(6%) missed by traditional surveillance. Pharmacy screen-
ing identified 80% of persons with TB who had received
their medications through health plan–reimbursed sources,
but missed those treated solely in public health clinics. The
positive predictive value of receiving more than two anti-TB
medications was 33%. Pharmacy data also provided useful
information about physicians’ management of TB and
patients’ adherence to prescribed therapy. Pharmacy data
can help public health officials to find TB cases and assess
their management in populations that receive care in the
private sector.
C
ontrolling and preventing tuberculosis (TB) continue
to be major public health challenges in the United
States (1). Information obtained through TB surveillance
ensures that TB-control activities are appropriate and can
be used to evaluate the effectiveness of public health pro-
grams (2). Because TB surveillance relies heavily on labo-
ratories and providers to report cases to local health depart-
ments, surveillance data can be compromised by
underreporting, particularly by private-sector clinicians
who treat TB infrequently. Pharmacy data, often available
in automated form, may supplement traditional TB report-
ing, especially because anti-TB medications are rarely
used to treat other conditions.
AMassachusetts study found that persons with TB who
were identified through pharmacy dispensing records and
who had not been previously reported to the state health
department represented 16% of all new cases (3). In that
study, receipt of two or more anti-TB drugs identified most
cases of active TB. These results suggested that pharmacy
dispensing information could supplement traditional TB
surveillance. In addition, pharmacy dispensing informa-
tion for persons with active TB provided useful informa-
tion about appropriateness of prescribed treatment
regimens and adherence to therapy (4).
We therefore evaluated the contribution of pharmacy
data to overall TB surveillance and to assessing the quali-
ty of TB management. We performed this study through
health plans to facilitate access to pharmacy dispensing
data and medical records.
Methods
Study Population
Members of three different health plans in Michigan
(1993–1999), Missouri (1996–1998), and Tennessee
(1998) were included in the study population. Study peri-
ods were based on availability of pharmacy data. 
All health plans met our basic criteria of providing most
of the medical care to defined populations, providing pre-
scription drug benefits, having automated pharmacy
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Therapeutics, Boston, Massachusetts, USAclaims files, and having accessible full-text medical
records. The health plans differed in some ways. Most
importantly, plan C (see below) routinely delegated care of
recognized TB patients to local health departments or had
members obtain their anti-TB drugs from public health
programs separate from the plan’s regular pharmacy pro-
grams and data systems. Additionally, the structure of the
three health plans and their populations differed; they con-
sisted of the following: a mixed staff and group model that
included a large urban population (plan A); an independent
practice association (IPA) health plan affiliated with a
managed-care organization, principally serving an
employed population (plan B); and a mixed IPA and staff
model, principally serving Medicaid enrollees (plan C).
Staff-model health plans employ providers who practice in
common facilities. IPA-model health plans contract with
providers who practice in their own offices (5). Prior insti-
tutional review board approval was obtained from partici-
pating health plans. 
Pharmacy Screening
Health plan pharmacy dispensing data were screened to
identify all members who received two or more anti-TB
medications during the study period. For plans A, B, and
C, we screened, respectively, approximately 1.3 million,
1.0 million, and 1.6 million health plan person-years. The
anti-TB medications included in the screening were isoni-
azid, rifampin, pyrazinamide, ethambutol, streptomycin,
ethionamide, kanamycin, cycloserine, capreomycin, para-
aminosalicylic acid (PAS), and drugs containing any com-
bination of these medications. Although at least 90% of
health plan members had some form of pharmacy benefit,
the plans varied considerably in directing their members to
public health facilities to obtain anti-TB medications. 
Identifying TB Cases
Reporting confirmed or clinically suspected TB to local
or state health departments by providers, laboratories,
boards of health, or administrators of hospitals is mandato-
ry in Michigan, Missouri, and Tennessee, which maintain
registries of all verified cases. State health department staff
in all three states determined whether health plan members
identified as having received two or more anti-TB medica-
tions had been reported previously to the health depart-
ments by matching to the state TB registries by using
previously described methods (6).
For all plan members who received two or more anti-
TB medications and who were not previously reported to
the state health departments, information was obtained
through review of medical records. A case of TB was
defined according to the Centers for Disease Control and
Prevention (CDC) surveillance definition (7). In a culture-
positive case, Mycobacterium tuberculosis was isolated
from a clinical specimen. In a smear-positive case, acid-
fast bacilli (AFB) were demonstrated in a specimen in the
absence of a culture. A clinical case-patient met all of the
following criteria: a positive tuberculin skin test, signs and
symptoms compatible with TB, and treatment with two or
more anti-TB drugs. Case-patients without a positive cul-
ture for M. tuberculosis that were not known to the health
departments were verified by review with clinicians expe-
rienced in diagnosing and treating TB.
To estimate the number of TB cases not detected by
using pharmacy data, each health plan’s membership dur-
ing the study period was matched to the state health depart-
ment’s TB registry entries during the same period by using
minimal disclosure methods (6). Potential matches were
confirmed with full identifiers. To determine the source of
care for patients not identified through pharmacy screen-
ing, health department records of all such patients in plans
A and B and a random sample in plan C were reviewed.
Assessing TB Management
Automated pharmacy dispensing records were used to
characterize TB therapy for persons with active TB who
met pharmacy screening criteria in plans A and B. Plan C
did not participate in the assessment of TB management
because members were routinely referred to public health
clinics for treatment, and information about medications
was unavailable from the health plan pharmacy database.
In addition, pharmacy dispensing records from two addi-
tional health plans affiliated with plan B were screened,
and TB cases verified through medical record review were
included in the analysis. 
All filled prescriptions were identified for isoniazid,
rifampin, pyrazinamide, ethambutol, streptomycin, ethion-
amide, kanamycin, cycloserine, capreomycin, PAS, and
drugs containing a combination of these medications.
Initial regimens, i.e., those dispensed at the start of thera-
py before susceptibility results were known, and final
treatment regimens were graded for consistency with
American Thoracic Society (ATS) and CDC guidelines in
effect at the time of diagnosis (8). The appropriateness of
doses based on patient weight was not evaluated.
Two measures were calculated for therapeutic adequa-
cy. The standard regimen dispensed is a percentage calcu-
lated by comparing the cumulative dose of each drug
dispensed with the total recommended. Each drug received
equal weight to a maximum of 100% per drug, as noted in
the following formula for a three-drug regimen: percent
standard regimen = ([D1/SR1] + [D2/SR2] + [D3/SR3]) x
(100/3), where DX is the cumulative dose for drug X and
SRX is the recommended total dose. Patients with a score
≥80% were considered to have received an appropriate
amount of anti-TB medication. The days without medica-
tion for isoniazid or another drug required for the duration
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days without medication (based on medication refill inter-
vals and quantities dispensed) by the number of days
between the first and last dispensing (4,9).
Analysis
The sensitivity of pharmacy data was defined as the
number of verified TB cases detected by pharmacy screen-
ing divided by the total number of verified TB cases iden-
tified through the TB registry, pharmacy data, or both
methods. The positive predictive value (PPV) of pharmacy
screening was defined as the number of verified TB cases
detected by pharmacy data divided by the total number of
persons meeting pharmacy screening criteria; persons with
undetermined case status were excluded. Exact binomial
confidence intervals were calculated for sensitivity and
PPV (8). 
Results
Dispensing Anti-TB Drugs 
A total of 244 patients received two or more anti-TB
drugs (Table 1). Of these, 13 (5%) met the TB case defini-
tion and had not been previously reported to their respec-
tive state health departments. Another 61 (25%) were
active TB case-patients. Sixty-three percent did not meet
the TB case definition, and the status of the remaining 7%
could not be determined because the medical records were
either unavailable or insufficient. 
Of 153 patients who received at least two anti-TB med-
ications but did not meet the CDC TB case definition, 62
(41%) were treated for suspected active TB. Of these, 15
(24%) received a full course of therapy for suspected
active TB. Twenty-one (14%) received more than one drug
during treatment for latent TB infection, 63 (41%) were
treated for non-TB mycobacterial infections, and 7 (4%)
were treated for noninfectious conditions or for unknown
reasons (Table 2).
The overall rate of initiating two or more anti-TB drugs
was 6 per 100,000 person-years, ranging from 3 to 11 per
100,000 person-years in the three health plans. Confirmed
case rates ranged from 0.9 to 4.3 per 100,000 person-years
screened. The 1998 TB incidence for the three states
ranged from 3.4 to 8.1 cases per 100,000 persons (9). For
persons meeting pharmacy screening criteria, the propor-
tion confirmed as new case-patients did not vary signifi-
cantly among the three plans (Table 1).
Newly Identified Cases of TB 
A total of 207 health plan members meeting TB case
definitions (53 in plan A, 22 in plan B, and 132 in plan C)
were identified through pharmacy data or health depart-
ment records (Table 3). Among these, 13 case-patients
(6%) were unknown to the respective state health depart-
ments. Two persons with TB unknown to one health
department had been reported to Mississippi State
Department of Health. None of the 13 were culture-posi-
tive for M. tuberculosis; one lacked a microbiology culture
but met the smear-positive case definition, and the remain-
ing 12 met the CDC TB clinical case definition. All except
one involved active pulmonary disease.
One hundred thirty-three TB cases were known to the
state health departments but were not identified through
pharmacy databases. We reviewed the records of 81 of
these patients, of whom 61 (75%) received their anti-TB
medications from public health clinics; this proportion
ranged from 58% (22/38) in plan A to 93% in plan C
(26/28). An additional 3 (4%) were treated at Veterans
Administration (VA) facilities or were diagnosed with TB
during hospitalization and died before discharge. Health
plan medical records did not include information about TB
diagnosis and treatment for 17 (21%) patients. Reasons for
this may include TB treatment exclusively by other
providers and incomplete documentation in accessible
medical records.
The overall sensitivity of the pharmacy screening
method to identify persons with active TB was 36% (28%
in plan A, 32% in plan B, and 39% in plan C). However,
the overall sensitivity was 80% after the extrapolated num-
ber of persons who received their TB medication from
public health clinics rather than the health plans was
excluded (Figure 1). The positive predictive value of the
pharmacy screening method to identify persons with active
TB was 33% (21% in plan A, 50% in plan B, and 36% in
plan C) (Figure 1). 
Assessing Management of TB
Of the 29 plan A (n = 15) and plan B (n = 14) members
with active TB identified through pharmacy screening,
health plan and health department records indicated that 17
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Table 1. Identification of tuberculosis (TB) cases by using pharmacy screening  
Cases  Plan A (%)  Plan B (%)  Plan C (%)  Total (%) 
Total no. dispensed 2 or more anti-TB drugs  73  28  143  244 
Matched to TB registry (previously reported TB cases)   12 (17)  6 (21)  43 (30)  61 (25) 
Previously unreported TB cases (verified by record review)   3 (4)  1 (4)  9 (6)
a  13 (5) 
Not a TB case (verified by record review)   55 (75)  7 (25)  91 (64)  153 (63) 
Case status not determined   3 (4)  14 (50)  0  17 (7) 
aIncludes two cases not f ound in the state health department’s TB registry but reported to other state health departments.  (59%) did not receive treatment in public health clinics and
were likely to have received their anti-TB medications
through health plan–reimbursed pharmacies. Twenty-eight
(97%) patients received initial regimens through pharma-
cies reimbursed by the health plan. In all instances, the ini-
tial regimen dispensed was appropriate. For all 17 patients
not treated in public health clinics, the final regimen
described in the medical record was adequate with regard
to the agents used, doses prescribed, and intended duration
of treatment. 
Fifteen of the 17 health plan–treated patients received
anti-TB medications for at least 70 days (compared to 3 of
13 who were treated outside the health plans [relative risk
= 3.8, p < 0.01]), with a median dispensing duration of 180
days (interquartile range 150–324 days). The median stan-
dard-regimen-dispensed score was 100% (interquartile
range 93%–100%) (Figure 2). Based on health plan phar-
macy data, one patient received an inadequate treatment
regimen, with a standard-regimen-dispensed percentage of
only 48%. Another health plan–treated patient received a
standard-regimen-dispensed score of 100% but had a days-
without-medication score of 51%, because of a gap in anti-
TB therapy of 143 days. One additional patient with
culture-positive M. tuberculosis infection received a stan-
dard-regime-dispensed score of 68% and a 60-day dura-
tion of dispensing. In all of these cases, the treating
physician did not describe noncompliance or document a
non–health plan source of anti-TB medications.
Discussion
TB surveillance has traditionally depended on reporting
by laboratories, public health clinics, hospitals, and private
practitioners. Several retrospective studies (3,10–13) indi-
cate that TB cases may be underreported, particularly
those without positive cultures. In this study, we found that
6% of all TB cases in the three participating health plans
had not been reported to state health departments. Most
cases missed by traditional surveillance were culture- and
smear-negative; however, nearly all patients with missed
cases had clinical evidence of pulmonary disease and were
therefore of public health interest. 
The recent shift of populations at risk for TB, includ-
ing Medicaid recipients, into managed care raises con-
cerns about reporting. As the proportion of patients with
TB who are cared for outside traditional public
health–funded clinics grows, the benefit of adjunct sur-
veillance methods based on pharmacy data is likely to
increase, since these data are available for a large segment
of the U.S. population.
Although we used health plan data for this study, health
departments could more efficiently obtain this information
directly from pharmacy benefits management companies
(PBMs) that act as intermediaries between managed-care
organizations and pharmacies, because they administer
and manage the prescription drug benefit programs for
these organizations. Working directly with PBMs has two
advantages. First, PBM information is accessible in real
time. Second, since the three largest PBMs in the United
States manage the pharmacy claims of approximately 200
million persons, information available from a small num-
ber of PBMs could provide a rich resource for public
health screening (14–17). 
The percentage of cases in these three health plans that
were missed by traditional surveillance (6%) was lower
than the 16% missed in the Massachusetts study (3). This
difference may reflect the fact that public health clinics
cared for more patients in these health plans than in
Massachusetts, where 60% of patients were treated solely
by health plan providers, compared to about 40% for these
health plans. 
Patients who received their anti-TB medications from
public health clinics were not identified through health
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Table 2. Reasons for meeting pharmacy screening criteria among persons without active tuberculosis (TB)  
Reasons why non -TB cases met screening criteria   Plan A (%)  Plan B (%)  Plan C (%)  Total (%) 
Suspected active TB, full course of therapy   7 (13)  0  8 (9)  15 (10) 
Suspected active TB, empiric therapy discontinued   12 (22)  0  35 (38)  47 (31) 
Treatment of latent TB infection   8 (14)  3 (43)  10 (11)  21 (14) 
Other mycobacterial infections   26 (47)  4 (57)  33 (36)  63 (41) 
Other or unknown   2 (4)  0  5 (5)  7 (4) 
Total  55  7  91  153 
Table 3. Detecting tuberculosis (TB) cases by using pharmacy screening and state health department TB registries  
Case identification   Plan A (%)  Plan B (%)  Plan C (%)  Total (%) 
Pharmacy screening only   3 (6)  1 (5)  9 (7)  13 (6) 
State health department only  (all cases)  38 (72)  15 (68)  80 (61)  133 (64) 
State health department only (health plan–treated patients)   16 (52)  2 (22)  0
a  18 (19) 
Both methods  12 (22)  6 (27)  43 (32)  61 (30) 
Total (all cases)   53  22  132  207 
Total (health plan–treated patients
b)  31  9  52  92 
aExtrapolated from review of a random sample of 28 of the 80 TB cases identified by the state health department and not by pharmacy screening.  
bExcludes TB patients receiving anti-TB medication from public health clinics; these medications are not included in the health plan pharmacy databases.  plans’pharmacy data. However, because these patients are
already known to the public health system, supplemental
surveillance methods are unnecessary. Pharmacy screening
identified 80% of the patients with TB who were not treat-
ed outside the health plan. This estimate is conservative;
we probably underestimated the number of persons receiv-
ing anti-TB medications from public health clinics or other
healthcare systems because we based this assessment on
the private providers’records. Intermittent enrollment may
also have compromised the sensitivity of pharmacy-based
screening. Larger databases that include pharmacy infor-
mation from multiple health plans within a geographic
area, such as those maintained by PBMs, are likely to
improve case-finding. 
The most common reasons for dispensing two or more
anti-TB medications to persons who did not meet the case
definition were 1) more than one drug used to treat latent
TB infection; 2) suspected active TB; 3) treatment of other
mycobacterial infections; and 4) treatment for suspected
active TB and receiving full courses of therapy, despite not
meeting the CDC surveillance definition for TB, based on
information available from their medical records. Persons
in the last category may warrant additional evaluation by
health departments because the case definition may not
detect all patients who meet clinical standards for treat-
ment. 
The PPV of pharmacy screening criteria may be lower
in clinical settings where treatment of non-TB mycobacte-
rial infections is common. One strategy to increase the effi-
ciency of pharmacy-based screening would be to use
microbiologic culture information to quickly identify and
exclude from further follow-up any persons with results
indicating mycobacterial species other than M. tuberculo-
sis. Complete laboratory reporting for M. tuberculosis is an
important prerequisite for efficiently implementing this
surveillance strategy.
In routine practice, pharmacy data might be used for
active TB case-finding, with direct reporting from organi-
zations dispensing drug information, such as health plans
or PBMs, to local or state health departments. These data
are typically available from health plans within 1 or 2
months and from PBMs within a day. Such reporting
would require verifying case status by health department
personnel. 
Obtaining and reviewing medical records for this study
were labor-intensive, but collecting this information from
providers in real time should be more efficient. The cost of
reporting would be relatively small for health plans or
pharmacy benefits managers, and the cost per person iden-
tified would be small for large organizations. The addition-
al costs for health departments to evaluate the status of
persons not already identified will vary considerably across
health departments. Despite the increased emphasis on pri-
vacy, current laws specifically allow reports of protected
health information to support public health activities.
Although pharmacy data may be useful, they will not
replace traditional surveillance of suspected and confirmed
TB cases. Because rapidly following-up suspected TB
cases is essential to prevent the spread of M. tuberculosis,
educating providers to report suspected cases promptly to
public health officials will continue to be important. 
Automated pharmacy data also provided useful infor-
mation about physicians’ management of TB and about
patients’ adherence to prescribed therapy. Monitoring
these aspects of TB care is particularly important when
care is decentralized or when patients receive care from
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Figure 1. Sensitivity and positive predictive value (PPV) of phar-
macy screening and percentage of tuberculosis (TB) cases detect-
ed only by pharmacy screening. *Of 28 members who met
pharmacy screening criteria, TB case status was verified for 14.
PPV calculation based on total of 14 with verified status. **Health
plan–treated patients excludes patients receiving anti-TB medica-
tion from public health clinics.
Figure 2. Pharmacy-dispensing profiles of tuberculosis (TB) case-
patients treated in the health plans and at least partially outside the
health plan. Percentage of standard regimen dispensed is plotted
against duration of dispensing anti-TB medications for the two
groups. A cutoff value of ≥70 days of medication dispensed from
health plan–reimbursed pharmacies identifies all but one of the
health plan–treated TB case-patients.more than one provider. Pharmacy information demon-
strated that, in nearly all cases, appropriate empiric regi-
mens were prescribed. In most cases managed by health
plan providers, full ATS/CDC-recommended regimens
were dispensed. Consistent with the Massachusetts study
results, using a cutoff value of at least 70 days of therapy
identified most patients treated solely within the health
plan. This practice is important in monitoring adherence to
therapy, since automated pharmacy information is com-
plete only for these patients. Pharmacy data also identified
several persons with evidence of suboptimal adherence to
therapy. Pharmacy information on anti-TB drugs could
thus be used for monitoring the appropriateness of case
management and to evaluate the program.
This study and our earlier work demonstrate that phar-
macy data may be useful in settings where TB care is pro-
vided by the private healthcare system. Centralized
repositories of pharmacy data, such as those maintained by
PBMs, may facilitate even more efficient application of
this surveillance strategy to find TB cases and assess TB
management for large patient populations. Similar studies
in other settings could expand our understanding of current
surveillance limitations and provide better estimates of the
true burden of TB in the United States. Similar strategies
could also be considered to augment traditional surveil-
lance for other diseases of public health importance.
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